LOS ANGELES, CA, March 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – With preparations underway for manufacturing the MIFTEC
Z-pinch (ZEBRA) Fusion Medical Isotope Generators, US Nuclear Corp. (OTCBB: UCLE) is one step closer to ending the dire worldwide
shortage of medical isotopes. The federal government is so desperate to find a domestic, stable supply of medical isotopes that
they recently announced over $60 million in funding to 8 projects/companies working on solutions for this demand. Of these 8
companies, only 3 have time-lines to supply medical isotopes in the near future, and of those 3, Magneto-Inertial Fusion
Technologies, Inc. (MIFTI, parent company to MIFTEC) has the most promising solution. MIFTEC’s patented fusion-powered medical
isotope generator is not only to solve the medical isotope shortage, their revolutionary process offers numerous advantages to
current production methods, including:
- MIFTEC’s process is fueled by a simple isotope of hydrogen from a renewable source: seawater.
Current production methods of medical isotopes are fission-based nuclear reactors or accelerators that require either highly
enriched or low enriched uranium (HEU/LEU) to operate. These methods are costly, multi-step processes that result in nuclear
waste byproducts that must be safely contained and stored for hundreds of years while being protected from theft by
terrorists.
- Due to the eco-friendly, fusion-based technology, the capital and operational costs are a fraction of that for fission or
accelerator technology. Additionally, medical isotope production costs are up to 50% less than all other current manufacturing
processes.
- The device is designed to fit into most hospitals, nuclear medicine clinics, and laboratories. It is ideal for local,
domestic production, and results in a major reduction in transportation and import costs. Local production also solves the
timeline issues of Mo-99’s 66-hour half-life.
- No production limit problem. Current methods to build a nuclear reactor or accelerator are time-consuming and expensive, and
once finally built, these facilities have a maximum production limit. There is currently around a $5 billion shortfall in
medical isotope production. US Nuclear to build MIFTEC’s medical isotope generators in a fraction of the time and cost,
with the production line continuing until demand has been filled.
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and,
consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect,"
"estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes,"
"predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These
forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially
from the expected results.
Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s
website at www.usnuclearcorp.com.
CONTACT: US Nuclear Corp. (OTCBB: UCLE) Robert I. Goldstein, President, CEO, and Chairman Rachel Boulds, Chief Financial Officer (818) 883 7043 Email: info@usnuclearcorp.com
